Metastatic Skin Cancer, Skin Squamous Cell Carcinoma
Conditions
Brief summary
This phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate whether treatment with avelumab plus cetuximab prolongs progression free survival (PFS) compared to avelumab alone. SECONDARY OBJECTIVES: I. To evaluate the confirmed objective response rate of each treatment arm. II. To evaluate the clinical benefit rate of each treatment arm. III. To evaluate the PFS of cetuximab plus avelumab in patients that have progressed on single agent avelumab. IV. To evaluate the overall survival (OS) for each treatment arm. V. To evaluate toxicity across treatment arms of avelumab plus cetuximab and avelumab alone. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive avelumab intravenously (IV) over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with avelumab failure will crossover to arm II. ARM II: Patients receive cetuximab IV over 1-2 hours on days 1, 8,15, and 22 and avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles for cetuximab and 24 cycles for avelumab in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months until disease progression, then every 6 months for up to 2 years.
Interventions
DRUGAvelumab
Given IV
DRUGCetuximab
Given IV
Sponsors
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* PRE-REGISTRATION ELIGIBILITY CRITERIA * Provide adequate tissue for PD-L1 testing \* Fresh tissue or archival tissue can be used. Sample must be at least core needle biopsy. Fine needle aspiration is not adequate. This specimen submission is mandatory prior to registration as results will be used for stratification * REGISTRATION ELIGIBILITY CRITERIA * • Biopsy-proven advanced cutaneous squamous cell carcinoma. Advanced disease is defined as either metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma not amenable to curative surgical resection, or the patient declines surgical resection * The patient must have at least one lesion that is measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy * This study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =\< 7 days prior to registration is required * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * If human immunodeficiency virus (HIV) positive the HIV viral load must be \< 200 copies/mL and CD4 count \> 200. If an HIV positive patient is on highly active antiretroviral therapy (HAART) the patient must have been so for \> 4 weeks * Absolute neutrophil count (ANC) \>= 1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Calculated creatinine clearance \>= 30 mL/min * Total bilirubin =\< 1.5 x upper limit of normal (ULN) * Aspartate aminotransferases (AST) / alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal (ULN)
Exclusion criteria
* Patients who received prior treatment with cetuximab as palliative treatment for advanced cutaneous squamous cell carcinoma (cSCC) are excluded. Patients that received cetuximab based chemoradiation (either definitive or adjuvant) as prior treatment for locally advanced disease are eligible as long as the last dosage was given \>= 6 months prior to registration * Patients who received prior cetuximab and had a severe infusion reaction requiring discontinuation of cetuximab are excluded * Patients treated with prior anti-PD-1 or anti-PD-L1 monoclonal antibodies (mAbs) are excluded * Patients cannot have received treatment with radiation or chemotherapy including another investigational agent within 2 weeks of registration. Other than as stated above for cetuximab there are no limits on the number of lines of other therapies given for advanced cSCC * Patients with a "currently active" second malignancy will be excluded with the exception of other non-melanoma skin cancers or cervical carcinoma in situ. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for 3 years * No history of the following: * Autoimmune disease (including inflammatory bowel disease) with the exception of patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment * Non-infectious pneumonitis that required steroids within 5 years * Organ transplant including prior stem cell transplant * Receipt of a live vaccine =\< 4 weeks * Cerebral vascular accident/stroke within 6 months of enrollment * Myocardial infarction within 6 months of enrollment * Active unstable angina * Congestive heart failure (\>= New York Heart Association Classification class II) * Serious cardiac arrhythmia requiring medication. Whether an arrhythmia is considered "serious" is at the discretion of the investigator * Active infection requiring systemic treatment * Use of immunosuppressive medication =\< 7 days of registration, EXCEPT for the following: * Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection) * Systemic corticosteroids at physiologic doses =\< 10 mg/day of prednisone or equivalent * Steroids as premedication for hypersensitivity reactions (e.g., computed tomography \[CT\] scan premedication)" * Other severe acute or chronic medical conditions including but not limited to immune colitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prolonging of Progression Free Survival (PFS) on Avelumab and Cetuximab Compared to Avelumab Alone | Time between registration and evidence of disease progression or death, assessed up to 2 years post treatment, up to 4 years | The study will be declared promising if, after the 37th PFS event, the hazard ratio is less than 0.758. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Confirmed Objective Response Rate (RR) | Up to 2 years post treatment, up to 4 years | A patient will be declared a success for RR if they achieve a partial response (PR) or better on two consecutive evaluations (at least 8 weeks apart). The number of successes will be divided by the number of evaluable patients to estimate the RR for each treatment arm and exact 95% confidence intervals will be calculated based on the properties of the binomial distribution. |
| Clinical Benefit Rate (CBR) | Up to 2 years post treatment, up to 4 years | The CBR will be estimated as the number of successes divided by the total number of evaluable patients. An exact 95% confidence interval will be constructed around the CBR using the properties of the binomial distribution. |
| PFS in Patients Who Have Progressed on Avelumab Alone | Time between registration and evidence of disease progression or death, assessed up to 2 years post treatment, up to 4 years | Will explore the PFS for those patients that crossover to combination therapy (avelumab + cetuximab) after progressing on avelumab alone (baseline time being the time of crossover). The Kaplan-Meier method will be used to calculate a median PFS as well as a 95% confidence interval. |
| Overall Survival (OS) | Time between enrollment and or death, assessed up to 2 years post treatment, up to 4 years | The Kaplan-Meier method will be used to calculate a median OS as well as a 95% confidence interval. |
| Incidence of Grade 3+ Adverse Events | Up to 30 days post treatment, up to 4 years | Will be described and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Maximum grade adverse events will be summarized in a tabular setting by treatment arm. |
Countries
United States
Contacts
STUDY_CHAIRDan P. Zandberg, MD
University of Pittsburgh Medical Center Hillman Cancer Center
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 72 years |
| Disease extent Distant only | 8 Participants |
| Disease extent Locoregional 1 distant | 11 Participants |
| Disease extent Locoregional only | 15 Participants |
| ECOG PS 0 | 23 Participants |
| ECOG PS 1 | 13 Participants |
| ECOG PS 2 | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 28 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants |
| HIV status Negative | 28 Participants |
| HIV status Positive | 0 Participants |
| Metastatic disease No | 12 Participants |
| Metastatic disease Yes | 34 Participants |
| PD-L1 status Negative | 7 Participants |
| PD-L1 status Positive | 21 Participants |
| Primary tumor site Anogenital | 1 Participants |
| Primary tumor site Extremities | 2 Participants |
| Primary tumor site Head and neck | 25 Participants |
| Primary tumor site Other | 3 Participants |
| Primary tumor site Trunk | 3 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 29 Participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 27 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 28 | 1 / 29 | 1 / 9 |
| other Total, other adverse events | 28 / 28 | 29 / 29 | 9 / 9 |
| serious Total, serious adverse events | 0 / 28 | 1 / 29 | 1 / 9 |
Outcome results
None listed